Prudential Financial Inc. purchased a new position in shares of Retrophin, Inc. (NASDAQ:RTRX) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 39,970 shares of the biopharmaceutical company’s stock, valued at approximately $775,000. Prudential Financial Inc. owned about 0.10% of Retrophin as of its most recent SEC filing.
Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. SG Americas Securities LLC raised its position in shares of Retrophin by 1.8% during the 2nd quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock worth $158,000 after purchasing an additional 146 shares during the last quarter. Legal & General Group Plc raised its position in shares of Retrophin by 4.3% during the 2nd quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock worth $168,000 after purchasing an additional 355 shares during the last quarter. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Retrophin during the 1st quarter worth about $185,000. Dynamic Technology Lab Private Ltd acquired a new position in shares of Retrophin during the 1st quarter worth about $219,000. Finally, Fox Run Management L.L.C. acquired a new position in shares of Retrophin during the 2nd quarter worth about $246,000.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of Retrophin stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $22.50, for a total transaction of $31,005.00. Following the completion of the transaction, the chief operating officer now owns 13,622 shares in the company, valued at $306,495. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 2.41% of the company’s stock.
Shares of Retrophin, Inc. (NASDAQ:RTRX) opened at 24.72 on Friday. Retrophin, Inc. has a 52 week low of $15.55 and a 52 week high of $25.44. The company’s 50-day moving average is $23.99 and its 200 day moving average is $20.09. The stock’s market cap is $948.88 million.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The business had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. The business’s revenue was up 16.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.07 EPS. Analysts forecast that Retrophin, Inc. will post ($1.13) earnings per share for the current fiscal year.
Several research analysts recently weighed in on the stock. ValuEngine downgraded shares of Retrophin from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. BMO Capital Markets restated a “buy” rating and set a $44.00 price target on shares of Retrophin in a research report on Friday. Finally, BidaskClub upgraded shares of Retrophin from a “hold” rating to a “buy” rating in a research report on Wednesday, August 16th. One analyst has rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $36.00.
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin, Inc. (NASDAQ:RTRX).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.